Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid Leukemia

Cancer Discovery

Volumn 4, Issue 3, 2014, Pages 362-675

  Pan, Rongqing ^a   Hogdal, Leah J ^b,c   Benito, Juliana M ^a   Bucci, Donna ^d   Han, Lina ^a   Borthakur, Gautam ^a   Cortes, Jorge ^a   Deangelo, Daniel J ^c   Debose, Lakeisha ^a   Mu, Hong ^a   Döhner, Hartmut ^g   Gaidzik, Verena I ^g   Galinsky, Ilene ^c   Golfman, Leonard S ^a   Haferlach, Torsten ^h   Harutyunyan, Karine G ^a   Hu, Jianhua ^a   Leverson, Joel D ^e   Marcucci, Guido ^d   Müschen, Markus ^f   Newman, Rachel ^a   Park, Eugene ^f   Ruvolo, Peter P ^a   Ruvolo, Vivian ^a   Ryan, Jeremy ^c   Schindela, Sonja ^h   Zweidler Mckay, Patrick ^a   Stone, Richard M ^c   Kantarjian, Hagop ^a   Andreeff, Michael ^a   Konopleva, Marina ^a   Letai, Anthony G ^b,c   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e ABBVIE INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; BH3 PROTEIN; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; IC 50; IMMUNOHISTOCHEMISTRY; MITOCHONDRION; MOUSE; MYELOBLAST; NONHUMAN; PROTEIN EXPRESSION; STEM CELL; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIPHENYL COMPOUNDS; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MITOCHONDRIA; NEOPLASMS, EXPERIMENTAL; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895788062     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0609     Document Type: Article

References (31)

1. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66-72.
2. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003;15:691-699.
3. Letai A, Bassik C, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-192.
4. Jabbour AM, Heraud JE, Daunt CP, Kaufmann T, Sandow J, O'Reilly LA, et al. Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ 2009;16:555-563.
5. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010;330:1390-1393.
6. Certo M, Del Gaizo Moore V, Nishino N, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-365.
7. Cheng EH, Wei MC, Weile SR, Flavell RA, TMak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-711.
8. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
9. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara G, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:909-916.
10. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
11. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663-1674.
12. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves anti-tumor activity while sparing platelets. Nat Med 2013;19:202-208.
13. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specifi c BH3 mimetic, has in vivo effi cacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013;121:2285-2288.
14. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013;24:120-129.
15. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388.
16. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012;151:344-355.
17. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno JS, Akashi K, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoi-etic stem cells. Science 2005;307:1101-1104.
18. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profi ling identifi es three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-185.
19. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Ve G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2001;334:1129-1133.
20. Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. MCL-1-depend-ent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol 2009;187:429-442.
21. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, et al. Updated results of a phase I fi rst-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). J Clin Oncol (suppl) 2013;31:abstr 7018.
22. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 2010;16:4217-4225.
23. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pet-tigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;10:1777-1784.
24. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prode-ath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-121.
25. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008;111:2300-2309.
26. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012;26:120-125.
27. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-1099.
28. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113:6215-6224.
29. Ruvolo VR, Karanjeet KB, Schuster TF, Brown R, Deng Y, Hinchcliffe E, et al. Role for PKC δ in fenretinide-mediated apoptosis in lymphoid leukemia cells. J Signal Transduct 2010;2010:584657.
30. Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, et al. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012; 119: 4971-4980.
31. Haferlach H, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, et al. Clinical utility of microarray-based gene expression profi ling in the diagnosis and subclassifi cation of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010;28:2529-2537.